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Hepatocellular carcinoma (HCC) is one of the most common malignant neoplasms in the
world and is the main cause of death in patients with liver cirrhosis. Surgical treatments
including hepatic resection and liver transplantation are considered as the most effective
treatment of HCC, however for various reasons, the vast majority of HCC patients are not
suitable for surgery. Radiofrequency ablation (RFA) is a local ablation technique designed
to destroy the tumor by heating. Alternating current passing from an electrode into the
surrounding tissue causes ions to vibrate and generate heat in the tissue. Increased current
leads to more vigorous ionic motion and increased temperature over a period of time,
eventually leading to coagulation necrosis and cell death. The purpose of RFA treatment
is complete tumor ablation with a margin of apparently normal tissue without collateral
damage. The efficacy of RFA can be assessed with contrast-enhanced ultrasound, contrast-
enhanced dynamic CT (CECT) or contrast-enhanced magnetic resonance imaging (MRI).
A successful RFA treated area of HCC is nonenhancing on CECT and tends to be larger
than the original tumor. A recent ablation area may have a circumferential rim of peripheral
hyperemia from the host inflammatory response to thermal injury, which usually subsides
a month after RFA. Discrete nodular noncircumferential enhancement, especially at the
ablation margin, would raises suspicions of residual or recurrent tumors. The result of per-
cutaneous RFA in the treatment of patients with HCC is very promising. The tumor size
and the Child-Pugh class are two significant predictors of survival in RFA-treated patients.
Comparative studies with surgical resection showed a promising survival rates with lower
complication comparable to those of surgical resection. The complication rate following
RFA varies from 2 to 10.6% and the mortality from 0 to 1.4%. In conclusion, RFA is a safe
and highly effective treatment of HCC, especially for small tumors less than 3 cm in size.
RFA technology and applications have progressed dramatically in the last few years. There
are now well-documented roles for its use in a variety of circumstances. Although surgery
is still the recommended treatment modality in patients with HCC, the majority of these
patients are not surgical candidates. In the future RFA will likely play a significant role with
a potential curative intent in the patients with HCC.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most
common malignant neoplasms in the world [1] and
is the main cause of death in patients with liver cir-
rhosis. Surgical treatments including hepatic resec-
tion and liver transplantation are considered as the
most effective treatment of HCC. Unfortunately, less
than 20–25% of HCC patients have been treated sur-
gically, mainly due to inadequate functional hepatic
reserve of related coexistent cirrhosis, the proximity
of the tumor to large vascular or biliary structures that
precluded a margin-negative resection, potentially
unfavorable biology with the presence of multiple
liver metastases, or multi-focal diseases [2,3].
Palliative treatments of patients with inoperable
HCC included transcatheter arterial chemoem-
bolization (TACE), percutaneous ethanol injection
(PEI), laser-induced interstitial themotherapy (LITT),
and local thermal ablation techniques. There are
five local thermal techniques: radiofrequency (RF),
laser, microwave, cryotherapy, and high intensity
focused ultrasound (HIFU) [4,5].
RFA mechanism
RF ablation (RFA) is a local ablation technique de-
signed to destroy the tumor by heating. The ability
to generate heat in biological tissue using alternat-
ing RF was first reported in the late 19th century.
RFA for treating tumors was first described in the
early 1990s, but the concept of using heat to treat
tumors is very old, and was used as far back as
Greek and Roman times, when cautery was used
to treat superficial tumors [6]. A RF current induces
ionic agitation that in turn results in heating. RF
has been used for many years to perform electro-
cautery in the operating room or to produce dis-
crete, focal lesions that interrupt aberrant cardiac
conduction pathways. Since its modern inception,
huge technical advances have been made in the field
of RFA. The methods of approach, including percu-
taneous, laparoscopic, or open type, the instruments
used, and the clinical applications continue to evolve
totally.
Initial electrodes were unipolar and of low power,
and were not internally cooled. Bipolar electrodes
are effective in small, discrete lesions but have had
limited usefulness in the treatment of liver tumors.
RFA is based on producing coagulative necrosis using
a high-frequency alternating current that is deliv-
ered through an electrode placed in the center of
the tumor [7,8]. Frictional heat is created by the
movement of ions within the tissue as the ions try
to follow this alternating current. Tissue necrosis be-
gins as the temperature approaches 50°C, and cellu-
lar proteins become denatured. RFA treatments often
result in local tissue temperatures that approach or
exceed 100°C, which result in parenchymal and
tumor cell death. Ultimately, the microvasculature
is destroyed as a result of thrombosis [6]. The radius
of surrounding tissue that is destroyed is depend-
ent on the impedance of the tissue and is inversely
proportional to the square of the distance from the
electrode [8]. As a result, tissues cool quite quickly
a short distance from the tip of the needle probe.
Proximity to large blood vessels also plays a signifi-
cant role in heat transmission. Blood flow protects
the vessel wall from damage but also acts as a “heat
sink” and cools nearby tissue, limiting coagulative
potential [9].
Several modifications of the needle electrodes
have been developed to enhance the coagulative
capability of the probes. Cooling of the probe tip
using an internal double lumen electrode for water
or saline infusion permits a wider radius of thermal
ablation because of the decreased local tissue imped-
ance and charring [10]. Local installation of cooled
solutions into the tumor bed, the wet electrode,
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has also been used to increase the conductance of
the electrical energy and volume of tumor destruc-
tion with success [11,12]. Multi-tined, expandable
array electrodes have produced very favorable re-
sults that permit a wider radius of tissue destruction
with less repositioning of the needle during treat-
ments and fewer overall sessions [13].
Equipment
At the moment three RF devices, all of which con-
sist of RF generators, have needle electrodes and
dispersive ground pads which are commercially
available [12–17]. The basic principles of each are
similar, but the operational techniques are different.
Generator power varies between 50 and 200 watts;
some are equipped with functions that display out-
put, tissue impedance, and temperatures in the 
tissue around the tip of a needle electrode. In each
device, the design of these electrodes is different.
The first device is the RITA model (RITA Medical
Systems, Mountain View, CA, USA). This consists of
a 50–150 watt electric generator and a 14-gauge
needle electrode, insulated except for its tip. Its hub
is a plunger that advances 4 or 7 prongs from the
tip, and when fully deployed, these and the needle
electrode resemble an open umbrella 3 to 5 cm in
diameter. All the prongs and uninsulated tip of the
needle are active electrodes, and each curved prong
contains a thermocouple at its tip that registers the
temperature of surrounding tissue.
The second device manufactured by Radio
Therapeutics Corporation (RTC device, Mountain
View, CA, USA) incorporates a 100-watt generator,
a LeVeen 15-gauge, monopolar array needle elec-
trode, and needle electrodes 2, 3, and 3.5 cm in
diameter, the largest of which is able to induce
lesions with a diameter of up to 4 cm. The 15-gauge
electrode consists of a 12 to 15 cm long insulated
cannula that advances ten individual hook-like
arms which are deployed after the needle has been
introduced into the tumor. The third device, manu-
factured by Radionics Corporation (Burlington,
MA, USA), includes a needle electrode whose tip is
internally cooled with chilled saline, a process de-
signed to increase the size of the thermal lesion.
The device is equipped with a 200-watt generator
and uses either a single 17-gauge straight electrode
or clustered electrodes designed in a triangular 
formation. With the third device, thermal lesions
of up to 5 cm in diameter can be induced.
Procedure and Technique
RF ablation can be performed percutaneously,
laparoscopically, or during laparotomy, and involves
conscious sedation or general anesthesia. Although
lesions can be reliably localized using CT, this part
of the procedure has depended mostly on sonog-
raphy [18–21]. For grounding, one or two large
dispersive pads are attached to the patient’s thigh
or back, and after skin cleansing using a sterile
technique, local anesthetic is injected along the
expected needle pathway and a small skin nick is
made. The electrode is passed through the nick and
advanced into the desired portion of the tumor,
using real-time sonography guidance. Once the
needle tip is appropriately positioned in the tumor,
the electrode prongs are deployed and ablation is
begun [22–24].
If the RITA device is used, initial ablation involves
partial deployment of the curved electrodes, but
once the temperature at the tip of these electrodes
reaches the desired level, they are fully deployed.
The temperature is then maintained at 95–100°C
for several minutes until the entire tumor or the
desired portion is ablated. After each ablation, the
prongs are retracted and the needle is reposi-
tioned. At this point, the needle tract is cauterized
and the needle withdrawn from the liver. With the
RTC device, the power used for initial ablation
after deployment of the multiple arrays is 50 watts,
and then increased gradually. At completion the
needle is removed with the multiple arrays retracted.
With the internal-cooling device either a single
electrode with 2 or 3 cm of exposed metallic tip or
a triple cluster electrode, depending on the size and
location of the tumor, can be employed. After the
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needle electrode is introduced into the tumor, RF
is usually applied for 12 minutes. To maintain a
temperature of 20–25°C in the tissue around the
needle tip, a peristaltic pump is used to infuse 0°C
normal saline solution into the lumen of the elec-
trodes. During ablation, the generator output, tissue
impedance and temperature around the needle tip
are continuously monitored.
For RF ablation to be successful and complete,
all malignant tissue must be ablated. The ideal goal
is to ablate a peripheral margin of 0.5–1 cm of nor-
mal hepatic tissue surrounding the tumor, as well
as the entire tumor itself. Without adequate safety
margins, an untreated viable tumor may remain,
leading to treatment failure and local recurrence.
In general, a single ablation, or two, may be ade-
quate for tumors less than 3 cm in diameter. For
larger tumors, however, multiple overlapping abla-
tions should be performed, according to tumor size.
With a needle electrode 3 cm in diameter, a single
ablation is applied for tumors < 2 cm in size, one or
two ablations for those which are 2–3 cm, and
multiple overlapping ablations for those >3 cm.
Indications and Contraindications
RFA is now used in a multitude of settings for a
variety of tumors. It was originally developed for
patients who were not surgical candidates, but its
use now has expanded to patients as a bridge to
liver transplantation and even as a substitute for
those who may be considered for surgical resec-
tion [25]. RFA has also been used to ablate kidney,
lung, adrenal, bone, soft tissue, breast, parathyroid,
and prostate tumors [26–30].
We currently limit the use of RF ablation to HCC
patients who are not considered for surgery, or
who decline this option [21]. As yet, there is no con-
sensus as to indication, but investigators generally
recommend that HCCs smaller than 5 cm in diam-
eter and fewer than five in number are ideal for RF
ablation. We are able to treat lesions larger than
this by making multiple overlapping ablations with
recently developed needle electrodes and powerful
generators, but it is known that the larger the tumor,
the greater the incidence of incomplete treatment
[19–22].
Liver transplantation has been used with cura-
tive intent for HCC, but its use is limited by organ
availability. The Milan criteria were developed to
determine which patients would be best suited for
transplant. Transplant candidates have one lesion
<5 cm or three or fewer lesions with the largest
being not >3 cm [31]. Transplantation provides the
advantage of both eradicating the tumor as well as
removing the diseased, cirrhotic liver in which new
tumors could arise if left in vivo [32]. A patient can
wait several months to more than a year on the
transplant list before a suitable donor becomes avail-
able, resulting in high dropout rates as a result of
primary tumor growth or the development of syn-
chronous or metastatic lesions that remove patients
from transplant eligibility [33]. Patients pretreated
with RFA were able to remain on the transplant list
for longer periods of time than their matched coun-
terparts, thus increasing their probability of receiving
a new liver.
Although RFA has been used with increasing fre-
quency, there are still some unresolved technical
limitations. For example, its use near the hilum of
the liver is limited not by the vascular structures but
by the potential for biliary stricture or fistula for-
mation, as the large bile ducts do not tolerate heat
well [34]. The well-documented “heat sink” effect of
nearby blood vessels and its limitation on local tissue
destruction has already been discussed. Caution
must also be employed when considering RFA in
lesions near the liver capsule or in close proximity to
a hollow intra-abdominal organ because perforation
can occur during the insertion of the probe or from
thermal injury [35,36]. The colon appears to be
more sensitive to this effect than the small bowel
or stomach. This may be avoided when an open or
laparoscopic approach is used rather than a percuta-
neous one [37]. More recently a fluid isolation tech-
nique using dextrose fluid has been performed to
displace any vulnerable organs away from the abla-
tion zone [38]. The same technique can be used to
render lesions in the dome near the diaphragm.
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Because RF ablation can cause bleeding, un-
correctable coagulopathy due to severe liver dys-
function is an absolute contraindication. The
prothrombin time ratio must be greater than 50%
and the platelet count greater than 60,000/mm3.
Patients with large amounts of ascites, obstructive
jaundice, evidence of extrahepatic tumors, or exten-
sive portal venous thrombosis are not suitable 
candidates for the procedure.
Imaging Assessment of Response 
after RFA
The purpose of RFA treatment is complete tumor
ablation with a margin of apparently normal tissue
without collateral damage [39]. Treatment efficacy
is improved by intra-procedure imaging assessment.
HCC can be assessed with contrast enhanced ul-
trasound [40–43]. Imaging performed after RFA is
important to evaluate the success of treatment,
detect a residual or recurrent tumor, and diagnose
new lesions. RFA uses alternating electric current
to produce ionic agitation and frictional heat in
targeted tissue, resulting in coagulation necrosis
and tumor desiccation. Complete ablation is dem-
onstrated by the absence of enhancement (Fig. 1).
Immediately after RFA it is common to see gas within
the ablation zone, possibly some hyper-attenuation
consistent with small amounts of hemorrhage and
following intravenous contrast reactive hyperemia
around the tumor. A recent ablation area may have
a circumferential rim of peripheral hyperemia from
the host’s inflammatory response to thermal injury,
which usually subsides within a month of RFA (Fig.
2). Contrast-enhanced dynamic CT (CECT) and dy-
namic MRI (CEMRI), performed 1 month after the
treatment, are accepted as reliable modalities for
evaluating the adequacy of RFA [39,44]. Despite its
limitations in predicting local tumor progression in
the treated tumors, real-time contrast enhanced
US provided results comparable to those obtained
with CECT/CEMRI in the detection of HCC tumor
vascularity and the assessment of response to RFA
after 1 month [40–43].
Findings from unenhanced CT show the area
after RFA as a low density lesion occupying the entire
volume of original tumor with a variable central area
of high attenuation from tumor desiccation. An
additional 5–10 mm of circumferential margin is
preferred as surgical safety margin. In a HCC with
an underlying cirrhotic liver, RFA heat may be con-
centrated within a well-encapsulated tumor and
does not usually extend to adjacent high impedance
cirrhotic tissue. Therefore a successful RFA treated
area of HCC tends to be the same size as the original
A B
Fig. 1. A 64-year-old man with a 4 cm HCC in Segment 7–8 of the liver received RFA treatment. The computed tomography scan
obtained 1 month after RFA. (A) Non-contrast enhanced computed tomography scan showed a central area of high attenuation
(arrowhead), representing greater cellular disruption which had usually disappeared by the time of the next follow-up scan. (B)
Contrast enhanced computed tomography scan showed no enhancement of the treated tumor area (arrow), representing total
necrosis of the HCC. 
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Fig. 2. A 78-year-old man with liver cirrhosis and HCC. (A) A 2 cm enhancing HCC (arrowhead) noted in segment 4 of liver on
arterial dominant phase of contrast enhanced computed scan before RFA. (B) Under sonography guided, the RFA probe was
inserted with the tip in the most distal part (arrow) of the hypoechoic tumor nodule (arrowheads). (C) Two minutes after RFA, lots
of microbubbles were produced and covered the whole hypoechoic lesion (arrowheads). (D) In the end of the RFA, microbubbles
migrated and gathered around the treated lesion (arrowheads). (E) Arterial dominant phase of contrast enhanced computed tomo-
graphy scan obtained 3 hours after RFA showed no enhancement of the treated lesion. Note that the treated area is larger than the
original lesion, representing the desired surgical safe margin. A thin circumferential peripheral enhancing rim (arrowheads) repre-
sents the hyperemia reaction. This enhancing rim usually spontaneously disappears 1 month after RFA.
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tumor. On CECT the ablation area is expected to
be nonenhancing. Discrete nodular noncircumfer-
ential enhancement, especially at the ablation mar-
gin, would raise suspicions of residual or recurrent
tumors (Fig. 3). Differentiation of reactive hyper-
emia from residual tumors may be difficult. Careful
comparison with imaging before ablation and close
follow-up are necessary in equivocal cases.
The MRI signals of coagulation necrosis after
RFA are intermediate to high signal to liver paren-
chyma on T1WI and low signal on T2WI, and no
enhancement after Gadolinium injection (Fig. 4).
Any discrete areas of a T1 hypointense and T2
hyperintense signal should raise the possibility of a
residual or recurrent tumor. However a recent abla-
tion area may have a heterogeneous signal on both
T1WI and T2WI because of nonuniform evolution
of inflammation and necrosis. The ablation area is
nonenhancing except for circumferential periph-
eral hyperemia, and a residual or recurrent tumor
usually manifests as a nodular enhancement after
Gadolinium enhanced MRI.
Clinical results of RFA of HCC
Most clinical results have demonstrated acceptable
safety and promising therapeutic efficacies. The
reported rates of major complications, mortality and
local tumor progression ranged 1.8–4.0%, 0–0.5%,
2.4–3.6%. The overall survival rates at 1, 3, 5 years
reported are 83–97%, 58–78%, 41–68% respec-
tively. The tumor free survival rates at 1, 3, 5 years
reported are 61–66%, 26–49%, 20–34%, respec-
tively. Comparative studies with surgical resection
showed a promising survival rates with lower com-
plication comparable to those of surgical resection.
Early RFA studies focused on its use as a stand-
alone therapy for patients with unresectable HCC.
While these trials contained valuable information
regarding treatment safety and response, they lacked
sufficient follow-up to define important long-term
outcomes such as survival. Recently large clinical
series have demonstrated 5-year post-RFA survival
rates between 33 and 55%, comparable to those
seen in series of hepatic resection [45–48]. Several
studies have evaluated long-term outcomes and
prognostic factors for patients with unresectable HCC
treated by conventional RFA. Guglielmi et al found
Child-Pugh class to be a significant predictor of sur-
vival in RFA-treated patients. While overall 3-year sur-
vival in all patients was 45%, the 3-year survival rate
of Child-Pugh A cirrhotics was significantly better
than that of Child-Pugh B cirrhotics (83% vs. 31%)
[49]. Lencioni et al observed favorable overall 5-year
survival rates in both the intention-to-treat (41%)
A B
Fig. 3. A 67-year-old man with a 4.5 cm HCC in segment 5 of the liver received RFA treatment. Computed tomography scan
obtained 1 month after RFA showed a focal peripheral enhancing area, representing the viable tumor. (A) Arterial dominant phase
of contrast enhanced computed tomography scan showed most of the tumor had total necrosis without enhancement, except a
1.2 cm sized enhancing viable tumor (arrowhead) in the anterior part of the treated area. (B) Portovenous phase of contrast
enhanced computed tomography scan showed early washout of the viable tumor part (arrowhead).
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and the actual treatment group (48%), and also
identified Child-Pugh class and tumor multiplicity as
the significant predictive variables for survival [45].
Some literature has also addressed the role of
novel RFA technologies in the management of HCC.
Two clinical series evaluated the use of expandable
and internally cooled electrode designs in RFA of
primary hepatic tumors. Shibata et al performed a
randomized trial comparing internally cooled elec-
trodes and expandable electrodes in 74 patients
with unresectable HCC underwent RFA. They ob-
served no difference between the two treatment
groups in terms of overall and disease-free survival
[50]. Buscarini et al compared conventional RFA
electrodes with expandable electrodes for the abla-
tion of unresectable HCC. While the mean number
of treatment sessions and local recurrence rates
were lower in the expandable electrode group, no
significant differences in the overall or disease-free






Fig. 4. A 71-year-old woman underwent RFA for a 3 cm HCC
in segment 6–7 of the liver (arrow). One month later follow-up
magnetic resonance imaging showed total necrosis of the tumor.
(A and B) T1WI imaging showed a high signal intensity change
in both in-phase: (A) and out-phase; (B) representing total
necrosis of the tumor with some proteinaceous or hemorrhagic
content. (C) T2WI imaging showed low signal intensity change,
which maybe be due to dehydrating effect of RF-induced ther-
mal damage. (D and E) Post Gadolinium enhanced T1WI
showed no enhancement both in the arterial dominant phase
(D) and portovenous phase (E).
designs [48]. Thus, all currently available electrode
designs are equivalent with respect to the long-
term and disease-free survival of HCC patients who
underwent RFA.
Giovannini et al evaluated the efficacy of inter-
nally cooled electrodes in 56 patients with HCC
and observed the overall and disease-free 3-year
survival rates were 94.2% and 70.3%, respectively.
Patients with alcoholic cirrhosis fared better than
those with a viral etiology: 2-year survival rates
were 77.7% in the alcoholic cirrhosis group versus
57.7% in the viral-induced cirrhotic group [23]. 
A study by Chen MS et al detailed 161 patients with
solitary HCC lesions <5 cm who were randomized
to either surgical resection or percutaneous ablative
therapy [51]. No significant difference was noted
in overall or disease-free survival rates at all intervals
up to 4 years between the two groups. This study
clearly provides support for the use of RFA in small
lesions (<5 cm) regardless of whether or not they
are amenable to surgical resection.
Sotiropoulos et al found patients with explanted
livers that demonstrated complete histologic tumor
necrosis after RFA had excellent short-term, disease-
free survival rates, supporting the need for complete
ablation of the lesion [52]. Nodule size appeared
to be the most important factor that correlated with
the degree of necrosis in a retrospective study of
30 HCC nodules by Pompili et al [53], with lesions
<3 cm demonstrating a higher rate of complete
destruction than larger nodules. Fifty-two patients
in a study by Lu et al [54] underwent RFA, with 41
of those patients going on to receive an orthotopic
liver transplant (OLT). None of the transplant
patients developed recurrent HCC after a mean of
14.9 months, and overall 1- and 3-year survival rates
were excellent at 85% and 76%, respectively.
In a prospective study by Mazzoferro et al, 50
cirrhotic patients with HCC were treated with RFA
prior to undergoing OLT. The actual 1- and 3-year
survival rates were 95% and 83%, respectively, with
only two patients dying of recurrent disease [55].
Their survival rates are superior to those of non-RFA-
treated patients who received transplants due to
HCC [56]. The use of RFA as a bridge to transplant
has proven to be an effective strategy. Control of
tumor size and the theoretical prevention of metasta-
tic disease formation allow patients to remain on the
organ waiting list for longer periods, increasing their
likelihood of obtaining a donor organ.
Larger lesions are known to be more difficult to
treat using RFA. Tumors > 3 cm in diameter often
require repositioning of the electrode or multiple
treatment sessions. However, even when using a
more aggressive approach, the efficacy of RFA has
been proven to be limited by tumor size [57].
Lesions measuring >5 cm have at best only a 50%
chance of being completely ablated [58]. Therefore,
most authors do not recommend the use of RFA
for tumors > 5–6 cm in diametere because of the
technical limitations of the current equipment used
and their inability to provide complete coagulative
necrosis [6].
Despite the size limitations of RFA, its use in un-
resectable HCC is significant. Those who are not
transplant candidates or are unable to undergo
resection face a dismal prognosis, and RFA provides
a chance for survival, especially for patients with
smaller lesions [59].
Complications
RFA is a minimally invasive technique, especially in
comparison with open surgical resection. However,
it still carries its own associated morbidity and mor-
tality in both the immediate postprocedure period
and over the long term. The complication rate fol-
lowing RFA varies from 2% to 10.6% and the mor-
tality from 0.1% to 1.4% [60–64]. Thermal injury
or needle puncture can result in subcapsular hema-
toma, occlusion of thrombosis of hepatic veins or
portal vein branches, bile duct strictures, or injury
to adjacent organs such as stomach, duodenum,
gallbladder, colon, diaphragm, lung or pleura.
Six hundred and eight consecutive patients who
underwent open or percutaneous RFA of malignant
hepatic tumors, both primary and metastatic, were
studied for both early and late complications [65].
Of the patients treated using an open technique,
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nearly half underwent concurrent resection. Early
complications such as symptomatic effusions, abscess
formation, hemorrhage, ascites, and biloma were
seen in 7.1% of patients. Patients who underwent
open RFA had a significantly higher early com-
plication rate (8.6%) than those who underwent
percutaneous RFA (4.4%); however, overall RFA-
related mortality was quite low, at 0.5%. Late com-
plications, those occurring more than 30 days after
RFA, were seen in 2.4% of patients and were not
statistically different between the open and percu-
taneous group. The only two predictive factors 
of RFA-associated complications were an open ver-
sus percutaneous approach and the presence of 
cirrhosis [65].
Complication rates increase with increasing
numbers of punctures, larger volumes of necrosis,
a more advanced Child-Pugh class, and the treat-
ment of lesions close to the diaphragm, into the
liver hilum, or close to vessels or viscera. The worst
morbidity is associated with infection of necrotic
ablated lesions and the major etiology for this is
the presence of a biliary endoprosthesis or a previ-
ous bilioenteric anastomosis. Some unusual com-
plications include hyperkalemia in patients with
chronic renal failure due to release of potassium
from disrupted cells [66], and rupture of exophytic
HCC and pacemaker malfunction if the pacemaker
lies in the path between the active electrode and
the grounding pads. Grounding pad burns were
also found in several studies. In patients with hip
replacements the grounding pads should be moved
from the thighs to places such as torso to avoid
burn injury.
Tumor seeding along the puncture tract has been
found too. Several mechanisms for tumor seeding
have been proposed. Viable tumor cells that adhere
to the RFA electrode can be disseminated along
the electrode tract during the removal. Tumor cells
may be carried into the tract with even a small
amount of bleeding. Cells may be forced into the
tract by sudden increases in intratumoral pressure
and this commonly occurs during RFA. Finally tumor
cells can be dislodged when saline is injected into
the tumor. Although an early study by Llovet et al
reported an extremely high rate (12.5%) [67], the
incidence of tumor seeding in other multicenter
studies is lower [62–64,68]. Livraghi et al reported
the incidence of tumor seeding along the course
of original electrode tract as 0.5%. These seeding
foci were seen 4 to 18 months following RFA and
75% of the tumors that developed tract seeding
were superficial in location [69]. To avoid tumor
seeding, the number of punctures and repeated
repositioning of the RFA needle electrode should
be minimized, the needle tract should be selected
to traverse normal liver parenchyma (particularly
in subcapsular tumors) and the tract should be
cauterized during the removal of electrode.
Conclusion
RFA is a safe and highly effective technique for the
local treatment of HCC, especially for small tumors.
The technology behind RFA and its many uses has
progressed dramatically in the past few years. RFA
has several advantages over other existing thera-
pies: it is minimally invasive, time saving, and for
the treatment of residual or recurrent tumors it can
be repeated. There are now well-documented roles
for its use in a variety of circumstances. Although
surgery is still the recommended treatment modal-
ity in patients with HCC, the majority of these
patients are not surgical candidates. In the future
RFA will likely play a significant role with a poten-
tial curative intent in the patients of HCC.
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